Allena Pharmaceuticals
ALNA
ALNA was delisted on the 7th of September, 2022.
29 hedge funds and large institutions have $28.1M invested in Allena Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 4 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1% less capital invested
Capital invested by funds: $28.3M → $28.1M (-$193K)
3% less funds holding
Funds holding: 30 → 29 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$980K |
| 2 |
Morgan Stanley
New York
|
+$494K |
| 3 |
Renaissance Technologies
New York
|
+$260K |
| 4 |
Millennium Management
New York
|
+$97.7K |
| 5 |
KAS
Kestra Advisory Services
Austin,
Texas
|
+$88.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$286K |
| 2 |
Two Sigma Advisers
New York
|
-$192K |
| 3 |
Two Sigma Investments
New York
|
-$56K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$36.6K |
| 5 |
HF
HRT Financial
New York
|
-$31K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HI
26
Harbour Investments
Madison,
Wisconsin
| $7K | +$3.03K | +2,500 | +83% |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| $5K | +$4.62K | +3,813 | +3,125% |
|
28
UBS Group
Zurich,
Switzerland
| $3K | -$8.81K | -7,274 | -74% |
|
29
Wells Fargo
San Francisco,
California
| $1K | +$38 | +31 | +3% |
|
|
30
Two Sigma Advisers
New York
| – | -$192K | -137,900 | Closed |
|
|
31
Two Sigma Investments
New York
| – | -$56K | -40,200 | Closed |
|
|
HF
32
HRT Financial
New York
| – | -$31K | -22,382 | Closed |
|
33
Barclays
London,
United Kingdom
| – | -$13K | -9,019 | Closed |
|
ALNA Hedge Fund Activity: Q2 2021 in Review
29 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Allena Pharmaceuticals (ALNA) for Q2 2021, worth a combined $28.1M — down 0.68% from $28.3M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ALNA and 3 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 10 added.
The largest buyer was Vanguard Group, adding an estimated $980K. The largest seller was Worth Venture Partners, cutting an estimated $286K.
- 29 institutional investors held Allena Pharmaceuticals (ALNA) as of Q2 2021, down from 30 in Q1 2021.
- Funds reported $28.1M of Allena Pharmaceuticals stock for Q2 2021, down 0.68% quarter-over-quarter.
- 3 funds opened new Allena Pharmaceuticals positions in Q2 2021 and 4 closed out, a net change of -1 holder.
- The largest Allena Pharmaceuticals buyer in Q2 2021 was Vanguard Group, an estimated $980K added.
- The largest Allena Pharmaceuticals seller in Q2 2021 was Worth Venture Partners, an estimated $286K sold.
Based on aggregated 13F filings for Q2 2021.